8-K: Applied DNA Sciences Reports Second Quarter Fiscal 2024 Results, Revenue Declines Due to COVID-19 Testing Contract End

Applied DNA Sciences' second quarter fiscal 2024 revenue decreased significantly due to the conclusion of a major COVID-19 testing contract, despite some growth in product revenue.

Summary

• Applied DNA Sciences announced its financial results for the second quarter of fiscal year 2024, which ended on March 31, 2024.
• Total revenue was approximately $930 thousand, a significant decrease from $4.4 million in the same quarter of the previous fiscal year.
• This $3.5 million revenue decrease was primarily due to a $3.6 million decline in COVID-19 testing services revenue, resulting from the end of a contract with the City University of New York (CUNY) in June 2023.
• Product revenue increased by $96 thousand, partially offsetting the decline in testing revenue.
• Gross profit decreased to $296 thousand from $1.8 million year-over-year, with the gross profit percentage dropping from 41% to 32%.
• Operating expenses decreased to $3.9 million from $4.5 million, due to reductions in selling, general, and administrative expenses and research and development expenses.
• The company reported a loss from operations of $3.6 million, compared to a loss of $2.7 million in the same period last year.
• Adjusted EBITDA was a negative $3.3 million, compared to a negative $2.1 million in the prior year.
• Cash and cash equivalents decreased to $3.1 million as of March 31, 2024, from $7.2 million as of September 30, 2023.
• A one-for-twenty reverse stock split was implemented on April 25, 2024.
• The company regained compliance with Nasdaq's minimum bid price requirement on May 10, 2024.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant revenue decline, increased losses, and a decrease in cash reserves. The company's reliance on a single contract and the lack of profitability are concerning.

Positives

• Product revenue increased by $96 thousand, indicating growth in non-COVID-19 related business.
• Operating expenses decreased by $600 thousand, showing efforts to control costs.
• The company regained compliance with Nasdaq's minimum bid price requirement.

Negatives

• Total revenue decreased significantly by $3.5 million due to the end of a major COVID-19 testing contract.
• Gross profit decreased to $296 thousand, with a lower gross profit percentage of 32%.
• The loss from operations increased to $3.6 million.
• Adjusted EBITDA was a negative $3.3 million, worsening from a negative $2.1 million in the prior year.
• Cash and cash equivalents decreased significantly to $3.1 million.

Risks

• The company's reliance on COVID-19 testing revenue has proven to be a significant risk, as evidenced by the large revenue drop.
• The company has a history of net losses and limited financial resources.
• There is uncertainty regarding future demand for biotherapeutics products and services.
• The company's ability to secure additional financing for manufacturing facilities is uncertain.
• There is limited market acceptance for the company's supply chain security products and services.
• The company faces the risk of declining demand for COVID-19 testing services.
• There is no commercial drug product utilizing PCR-produced DNA technology approved for therapeutic use.

Future Outlook

The company's future performance is subject to various risks and uncertainties, including the demand for its biotherapeutics products and services, its ability to secure additional financing, and market acceptance of its products. The company undertakes no obligation to update forward-looking statements.

Management Comments

• The company will not host a financial webcast or call for this most recent quarterly reporting period.
• The company will host an investor update call on June 12, 2024.

Industry Context

The decline in revenue due to the end of a COVID-19 testing contract highlights the volatility of the diagnostics market and the need for companies to diversify their revenue streams. The company's focus on DNA technologies and biotherapeutics aligns with broader trends in the biotechnology industry, but it faces competition and challenges in commercializing its products.

Comparison to Industry Standards

• Applied DNA's revenue decline is significant compared to other companies that have diversified their revenue streams beyond COVID-19 testing.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) have shown more resilience in their revenue growth by focusing on broader cancer diagnostics and precision medicine.
• The decrease in cash and cash equivalents is concerning compared to companies with stronger balance sheets, such as Illumina (ILMN) and Thermo Fisher Scientific (TMO).
• The negative Adjusted EBITDA is also a concern compared to companies that have achieved profitability or are on a clear path to profitability.

Stakeholder Impact

• Shareholders will likely be negatively impacted by the poor financial results and the reverse stock split.
• Employees may be concerned about the company's financial stability.
• Customers may be concerned about the company's ability to continue providing services.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• The company will host an investor update call on June 12, 2024.

Key Dates

Keywords

DNA technologies, PCR, COVID-19 testing, molecular diagnostics, genetic testing, supply chain security, biotherapeutics, RNA polymerase, reverse stock split, Nasdaq compliance